The study looked at cases diagnosed between 2005 and 2016, during which time federal guidelines began recommending against prostate-specific antigen, or PSA, screening for prostate cancer detection because of concerns that the overall benefits of the once routinely recommended blood test did not outweigh the risks.
The prostate cancer trends observed in the new study “likely” resulted from the recommendations against screening, leading to undetected cases that advanced, lead author Ahmedin Jemal, scientific vice president for surveillance and health services research at the American Cancer Society, speculated.
Each year in the United States, there are about 192,000 new cases of prostate cancer and 33,000 deaths. Thankfully, most cases are slow-growing and not life-threatening. Many cases can take a decade or more to show symptoms, if at all, and may never be fatal.
U.S. & World
Read the full story at NBC News.com.